Development of tolerance to the antinociceptive effect of systemic morphine at the lumbar spinal cord level: a c-Fos study in the rat.
The development of tolerance to the antinociceptive effects of morphine was investigated in rats using carrageenin-induced spinal c-Fos expression. We took advantage of this technique to especially study, at the cellular level, in freely moving animals, the development of tolerance based on the visualization of dorsal horn spinal cord neurons which play a major role in nociceptive processes. Two hours after intraplantar injection of carrageenin (6 mg/150 microliter of saline), c-Fos-like immunoreactivity (FLI) was observed predominantly in the superficial and deep laminae of the dorsal horn in segments L4 and L5 of the spinal cord. In naive rats, acute intravenous morphine (3 mg/kg, i.v.) reduced the number of superficial and deep FLI neurons; 49% and 59% reduction respectively (p<0.0001 for both). In morphine-pretreated rats (daily administration of subcutaneous morphine: 1, 3, 5, 10, 20 or 40 mg/kg once a day for 4 days), antinociceptive tolerance tested on day 5 by acute morphine (3 mg/kg, i.v.) was manifest in those groups pretreated with the highest doses of morphine (10, 20 or 40 mg/kg). From regression analysis, it appeared that tolerance to the antinociceptive effect of morphine developed progressively as a function of the chronic morphine dose used on neurons involved in spinal nociceptive processes (superficial and deep dorsal horn neurons). Similarly, in rats pretreated with 10 mg/kg of morphine over 1, 2, 3 or 4 days, tolerance progressively developed, for both spinal neuronal populations, as a function of the duration of the pretreatment. These results are discussed in the context of the several possible sites of action of morphine.
Le Guen
S
S
Unité de Recherche de Physiopharmacologie du Système Nerveux, INSERM U. 161 and EPHE, 2 rue d' Alésia, 75014, Paris, France. leguen@broca.inserm.fr
Catheline
G
G
Besson
J M
JM
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D002351:Carrageenan; D004361:Drug Tolerance; D005079:Excipients; D006930:Hyperalgesia / Q000209:etiology; D007249:Inflammation / Q000150:complications; D008161:Lumbosacral Region; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D010146:Pain / Q000503:physiopathology*; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012044:Regression Analysis; D013116:Spinal Cord / Q000187:drug effects*
D000701:Analgesics, Opioid; D005079:Excipients; D009419:Nerve Tissue Proteins; D016760:Proto-Oncogene Proteins c-fos; D009020:Morphine; D002351:Carrageenan